The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Biologics vs. small molecules: Drug costs and patient access
Open accessAbstract
Significant advances in drug research and development are herein reviewed first to set the background for a critical consideration of the economic sustainability of biologics and small molecules, why biologic drugs are more expensive, and how drug cost often influences patient access to one drug class over the other. Also strongly emphasized is the need for the drug-making, especially the biopharmaceutical, industry to consider a reassignment of priorities so that more patients can enjoy the great benefits that come with blockbuster drugs, many of which are of biological origin but extremely expensive. A balance between the efficacy of wonder-performing drugs and the patient's financial ability to access them must be established to obliterate the crippling effect of the high costs of drugs on the poor majority of patients – those who cannot afford them. The overarching point broadly emphasized is that the actual success in drug discovery and development and in healthcare delivery should be measured not only by the magnitude of scientific breakthroughs but also by the level to which they are affordable to patients as determined by their costs. To enhance patients' access to drugs and new and/or improved healthcare technologies, more research attention must be paid to such cheaper alternatives as small molecules generics, biosimilars, and antibody-drug conjugates; government policies must be established to encourage the commercialization of biosimilars; and pharmaceutical companies must be charitable enough to run assistance programs for eligible financially handicap patients while seeking to make profits from the drug-making business.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The structure and function of G-protein-coupled receptors
Rosenbaum, D. M., Rasmussen, S. G. F., & Kobilka, B. K. (2009) · Nature · doi:10.1038/nature08144 · Cited by 2,534
Inducible Apoptosis as a Safety Switch for Adoptive Cell Therapy
Di Stasi, A., Tey, S.-K., Dotti, G., Fujita, Y., Kennedy-Nasser, A., Martinez, C., Straathof, K., Liu, E., Durett, A. G., Grilley, B., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1106152 · Cited by 1,512
Enumeration of 166 Billion Organic Small Molecules in the Chemical Universe Database GDB-17
Ruddigkeit, L., van Deursen, R., Blum, L. C., & Reymond, J.-L. (2012) · Journal of Chemical Information and Modeling · doi:10.1021/ci300415d · Cited by 1,505
Roland, L., Grau, M., Matena, J., Teske, M., Gieseke, M., Kampmann, A., Beyerbach, M., Murua Escobar, H., Haferkamp, H., Gellrich, N.-C., et al. (2015) · International Journal of Molecular Sciences · doi:10.3390/ijms17010001 · Cited by 862
Management of toxicities of immune checkpoint inhibitors
Spain, L., Diem, S., & Larkin, J. (2016) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2016.02.001 · Cited by 854
Antibody–Drug Conjugates: A Comprehensive Review
Khongorzul, P., Ling, C. J., Khan, F. U., Ihsan, A. U., & Zhang, J. (2020) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-19-0582 · Cited by 787
Baricitinib in Patients with Refractory Rheumatoid Arthritis
Genovese, M. C., Kremer, J., Zamani, O., Ludivico, C., Krogulec, M., Xie, L., Beattie, S. D., Koch, A. E., Cardillo, T. E., Rooney, T. P., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1507247 · Cited by 627
Antibody–drug conjugates as novel anti-cancer chemotherapeutics
Peters, C., & Brown, S. (2015) · Bioscience Reports · doi:10.1042/bsr20150089 · Cited by 492
Harris, P. A., Berger, S. B., Jeong, J. U., Nagilla, R., Bandyopadhyay, D., Campobasso, N., Capriotti, C. A., Cox, J. A., Dare, L., Dong, X., et al. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b01751 · Cited by 480
Aminoglycoside Antibiotics in the 21st Century
Becker, B., & Cooper, M. A. (2013) · ACS Chemical Biology · doi:10.1021/cb3005116 · Cited by 419
Cited by
Rankin-Turner, S., Vader, P., O'Driscoll, L., Giebel, B., Heaney, L. M., & Davies, O. G. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.04.012 · Cited by 161
The Dawn of a New Era: Targeting the “Undruggables” with Antibody-Based Therapeutics
Qian, L., Lin, X., Gao, X., Khan, R. U., Liao, J.-Y., Du, S., Ge, J., Zeng, S., & Yao, S. Q. (2023) · Chemical Reviews · doi:10.1021/acs.chemrev.2c00915 · Cited by 155
Standardization Approaches for Extracellular Vesicle Loading with Oligonucleotides and Biologics
Roerig, J., & Schulz‐Siegmund, M. (2023) · Small · doi:10.1002/smll.202301763 · Cited by 67
Tan, X., Huang, Z., Pei, H., Jia, Z., & Zheng, J. (2024) · iScience · doi:10.1016/j.isci.2024.110712 · Cited by 66
Makowska, K., Nowaczyk, J., Blicharz, L., Waśkiel-Burnat, A., Czuwara, J., Olszewska, M., & Rudnicka, L. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24010781 · Cited by 63
Metadata
- Authors
- Makurvet, F. D.
- Venue
- Medicine in Drug Discovery
- Publisher
- Elsevier BV
- Published
- 2021-03
- Volume
- 9
- Pages
- 100075
- ISSN
- 2590-0986 (ISSN-L)
- OpenAlex
- W3107028140
- Cited by
- 271
- References
- 32
- FWCI
- 23.20
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Biologics vs. small molecules: Drug costs and patient access. https://app.cochat.ai/papers/10.1016/j.medidd.2020.100075
- The paper
- Makurvet, F. D. (2021). Biologics vs. small molecules: Drug costs and patient access. Medicine in Drug Discovery. https://doi.org/10.1016/j.medidd.2020.100075
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.